Japan’s Contribution

<NTD-related investment through the GHIT fund>

Amount invested
Number of investments

The GHIT Fund (Global Health Innovative Technology Fund) is a global nonprofit organization established on November 6, 2012. It is a public-private partnership between the Japanese government (Ministry of Foreign Affairs and Ministry of Health, Labour and Welfare), six Japanese pharmaceutical companies (Astellas Pharma, Eisai, Shionogi, Daiichi Sankyo, Takeda Pharmaceutical, and Chugai Pharmaceutical), the Bill & Melinda Gates Foundation, the Wellcome Trust, and the United Nations Development Programme. The organization invests funds in the development of drugs, vaccines, and diagnostic reagents for infectious diseases for use in developing countries.

<NTD-related projects at AMED>

Number of projects selected

AMED (the Japan Agency for Medical Research and Development) is a national research and development agency within the Cabinet Office that was established on April 1, 2015. It is engaged in comprehensive initiatives to promote integrated systems for carrying medical R&D projects from the basic research phase to the implementation phase, strengthen systems to enable smooth translation of research results into practical solutions, and improve R&D infrastructure. It promotes R&D and improves R&D infrastructure in the NTD field through projects such as the Science and Technology Research Partnership for Sustainable Development (SATREPS), which is combined with Official Development Assistance (ODA); the Strategic International Collaborative Research Program (SICORP), which is a joint research program based on intergovernmental agreements, and the e-ASIA Joint Research Program (e-ASIA JRP), which is an international joint research initiative formed by East Asia Summit member countries. It also supports establishment of hub offices in African countries and joint global research on NTD control in Africa.

Japan’s Contribution